2640292-37-9
Chemical Structure
DDO-6600
- CAS No.: 2640292-37-9
- Formula:C26H28N4O2
- Molecular Weight:428.53
IUPAC Name: (R)-1-((2S,3S,4aR,5R,7S,8S,8aS)-8-(benzyloxy)-2,3,7-trimethoxy-2,3-dimethylhexahydro-5H-pyrano[3,4-b][1,4]dioxin-5-yl)prop-2-en-1-ol
InChIKey: SKDKPKFZKHHGCG-BUHFOSPRSA-N
SMILES: O=C(N1C(CCCC1)C(N)=O)/C=C/C2=CN(C3=CC=CC=C3)N=C2C4=CC(C)=C(C=C4)C
Biological Activity: DDO-6600 is a covalent Hsp90 inhibitor. DDO-6600 disrupts the interaction between Hsp90 and its co-chaperone protein Cdc37, thereby inducing the degradation of kinase client proteins (such as AKT, CDK4, c-Raf). DDO-6600 has inhibitory activity against various cancer cells. DDO-6600 inhibits the migration and invasion of HCT-116 cells, and induces cell cycle arrest and apoptosis. DDO-6600 significantly inhibits tumor growth in the HCT-116 xenograft tumor model. DDO-6600 can be used for research on colorectal cancer[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DDO-6600 | 98.19% | DDO-6600 is a covalent Hsp90 inhibitor. DDO-6600 disrupts the interaction between Hsp90 and its co-chaperone protein Cdc37, thereby inducing the degradation of kinase client proteins (such as AKT, CDK4, c-Raf). DDO-6600 has inhibitory activity against various cancer cells. DDO-6600 inhibits the migration and invasion of HCT-116 cells, and induces cell cycle arrest and apoptosis. DDO-6600 significantly inhibits tumor growth in the HCT-116 xenograft tumor model. DDO-6600 can be used for research on colorectal cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
